A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

Exclusion Criteria

• •Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements.
• •Received prior systemic anticancer therapy for their metastatic NSCLC.
• •Known additional malignancy that is progressing or has required active treatment within the past 3 years.
• •Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• •Active autoimmune disease that has required systemic treatment in the past 2 years.
• •History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
• •Active infection requiring systemic therapy.